A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX7353 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX7353 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs BCX 7353 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 08 Feb 2016 Results from this trial are expected by the end of 2016, according to a BioCryst media release.
    • 08 Oct 2015 Status changed from recruiting to completed, according to a BioCryst Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top